세계의 길랭 바레 증후군 진단 시장 : 시장 규모의 분석 및 예측 - 검사별, 최종 용도별, 지역별(2022-2032년)

The global Guillain-Barre Syndrome (GBS) diagnostics market was valued at approximately USD 180.22 million in 2023 and is anticipated to expand at a CAGR of 2.8% during the forecast period from 2024 to 2032. This growth is primarily driven by the increasing incidence of Guillain-Barre Syndrome, advancements in diagnostic techniques, and heightened awareness of neurological disorders among healthcare professionals and the general population. With early diagnosis playing a crucial role in patient outcomes, demand for innovative diagnostic methods, including nerve conduction studies (NCS), electromyography (EMG), and biomarker-based testing, is on the rise.

Guillain-Barre Syndrome is a rare but severe autoimmune disorder in which the body's immune system attacks the peripheral nervous system, leading to muscle weakness, paralysis, and, in some cases, respiratory failure. It affects individuals across all age groups, but the highest prevalence is observed in people aged 30 to 50 years. According to the Centers for Disease Control and Prevention (CDC), approximately 3,000 to 6,000 cases of GBS are reported annually in the U.S. alone. Recently, in January 2025, a cluster of 67 GBS cases was identified in Pune, India, highlighting the need for more effective diagnostic tools. Given the link between GBS and viral infections, such as COVID-19 and Zika virus, early and accurate diagnosis is critical in managing patient care and treatment.

The aging global population is also a significant driver for the market. According to the World Health Organization (WHO), by 2030, one in six individuals worldwide will be over the age of 60, making them more vulnerable to autoimmune disorders, including GBS. The rising prevalence of age-related neurodegenerative diseases further underscores the urgent need for improved diagnostic methodologies. Additionally, emerging AI-driven diagnostic tools are enhancing the speed and accuracy of GBS detection, contributing to the market's overall growth.

North America currently holds the largest market share, driven by strong healthcare infrastructure, higher awareness levels, and rapid adoption of advanced diagnostic technologies. In the United States, the market is expanding due to government initiatives supporting rare disease research and investments in precision diagnostics. Meanwhile, Asia Pacific is anticipated to witness the highest growth rate, fueled by rising healthcare expenditures, increasing disease prevalence, and expanding diagnostic capabilities in countries like China, Japan, and India. The European market is also witnessing significant growth, supported by stringent regulatory frameworks and the adoption of cutting-edge medical diagnostics.

Major Market Players Included in This Report Are:

• Cadwell Industries, Inc.
• Natus Medical Incorporated
• Nihon Kohden Corporation
• Medtronic plc
• Bionen Medical Devices
• Deymed Diagnostic
• Neurosoft
• Alpine Biomed
• EMS Biomedical
• Rochester Electro-Medical, Inc.
• Compumedics Limited
• Medica Corporation
• Micromed Group
• Neurovirtual
• Noraxon USA Inc.

The Detailed Segments and Sub-Segments of the Market Are Explained Below:

By Test:

• Lumbar Puncture
• Nerve Conduction Studies
• Electromyography
• Others

By End-use:

• Hospitals & Clinics
• Diagnostic Laboratories
• Others

By Region:

• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Rest of Asia Pacific
• Latin America
• Brazil
• Argentina
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• UAE
• South Africa
• Rest of Middle East & Africa

Years Considered for the Study Are as Follows:

• Historical Year: 2022
• Base Year: 2023
• Forecast Period: 2024 to 2032

Key Takeaways:

• Market estimates & forecasts for 10 years (2022-2032)
• Annualized revenues and regional-level analysis for each market segment
• Country-level analysis across key geographies
• Competitive landscape insights, including market shares of key players
• Strategic recommendations for emerging market entrants and established players
• Analysis of disruptive technologies shaping the market
• Demand-side and supply-side factors influencing market dynamics

Table of Contents

Chapter 1. Global Guillain-Barre Syndrome Diagnostics Market Executive Summary

• 1.1. Global Guillain-Barre Syndrome Diagnostics Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Test
  • 1.3.2. By End-use
• 1.4. Key Market Trends
• 1.5. Recession Impact on Market Growth
• 1.6. Analyst Recommendations & Conclusion

Chapter 2. Global Guillain-Barre Syndrome Diagnostics Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability of Diagnostic Tools
    • 2.3.3.2. Technological Innovations in Diagnostic Equipment
    • 2.3.3.3. Regulatory Frameworks & Compliance
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Patient's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Increasing Prevalence of Guillain-Barre Syndrome
    • 2.3.4.2. Advancements in AI-based Diagnosis
    • 2.3.4.3. Rising Awareness and Early Diagnosis Initiatives
    • 2.3.4.4. Government Funding for Neurological Disorder Research
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Guillain-Barre Syndrome Diagnostics Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Increasing Incidence of Guillain-Barre Syndrome Worldwide
  • 3.1.2. Technological Advancements in Nerve Conduction Studies & Biomarker Testing
  • 3.1.3. Higher Awareness and Early Diagnosis of Autoimmune Disorders
  • 3.1.4. Growth in the Geriatric Population Susceptible to GBS
• 3.2. Market Challenges
  • 3.2.1. High Costs Associated with GBS Diagnostic Tests
  • 3.2.2. Limited Availability of Specialized Diagnostic Laboratories in Developing Regions
  • 3.2.3. Stringent Regulatory Approvals for New Diagnostic Techniques
• 3.3. Market Opportunities
  • 3.3.1. Integration of Artificial Intelligence & Machine Learning in Diagnostics
  • 3.3.2. Increasing Investment in Research & Development for Advanced Biomarkers
  • 3.3.3. Expansion of Point-of-Care Diagnostic Solutions for GBS

Chapter 4. Global Guillain-Barre Syndrome Diagnostics Market Industry Analysis

• 4.1. Porter's Five Forces Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. PESTEL Analysis
  • 4.2.1. Political Factors
  • 4.2.2. Economic Factors
  • 4.2.3. Social Factors
  • 4.2.4. Technological Factors
  • 4.2.5. Environmental Factors
  • 4.2.6. Legal Factors
• 4.3. Investment Opportunities in GBS Diagnostics
• 4.4. Emerging Trends in Guillain-Barre Syndrome Diagnostics
• 4.5. Industry Expert Perspectives
• 4.6. Analyst Recommendations & Conclusion

Chapter 5. Global Guillain-Barre Syndrome Diagnostics Market Size & Forecast by Test (2022-2032)

• 5.1. Segment Dashboard
• 5.2. Global Guillain-Barre Syndrome Diagnostics Market: Test Revenue Trend Analysis, 2022 & 2032 (USD Million)
  • 5.2.1. Lumbar Puncture
  • 5.2.2. Nerve Conduction Studies
  • 5.2.3. Electromyography
  • 5.2.4. Others

Chapter 6. Global Guillain-Barre Syndrome Diagnostics Market Size & Forecast by End-use (2022-2032)

• 6.1. Segment Dashboard
• 6.2. Global Guillain-Barre Syndrome Diagnostics Market: End-use Revenue Trend Analysis, 2022 & 2032 (USD Million)
  • 6.2.1. Hospitals & Clinics
  • 6.2.2. Diagnostic Laboratories
  • 6.2.3. Others

Chapter 7. Global Guillain-Barre Syndrome Diagnostics Market Size & Forecast by Region (2022-2032)

• 7.1. North America
  • 7.1.1. U.S.
  • 7.1.2. Canada
  • 7.1.3. Mexico
• 7.2. Europe
  • 7.2.1. UK
  • 7.2.2. Germany
  • 7.2.3. France
  • 7.2.4. Italy
  • 7.2.5. Spain
  • 7.2.6. Rest of Europe
• 7.3. Asia Pacific
  • 7.3.1. China
  • 7.3.2. India
  • 7.3.3. Japan
  • 7.3.4. South Korea
  • 7.3.5. Australia
  • 7.3.6. Rest of Asia Pacific
• 7.4. Latin America
  • 7.4.1. Brazil
  • 7.4.2. Argentina
  • 7.4.3. Rest of Latin America
• 7.5. Middle East & Africa
  • 7.5.1. Saudi Arabia
  • 7.5.2. UAE
  • 7.5.3. South Africa
  • 7.5.4. Rest of Middle East & Africa

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
  • 8.1.1. Cadwell Industries, Inc
  • 8.1.2. Natus Medical Incorporated
  • 8.1.3. Nihon Kohden Corporation
• 8.2. Market Share Analysis of Major Players
• 8.3. Key Growth Strategies Adopted by Market Leaders
• 8.4. Company Profiles

Chapter 9. Research Process

• 9.1. Research Methodology
  • 9.1.1. Data Mining
  • 9.1.2. Market Estimation Techniques
  • 9.1.3. Validation Process
  • 9.1.4. Data Source & References
• 9.2. Research Attributes